Drug Search Results
More Filters [+]

Baminercept

Alternative Names: baminercept, bg-9924, bg9924, bg 9924
Latest Update: 2021-12-01
Latest Update Note: PubMed Publication

Product Description

Baminercept, an LTbetaR-Ig fusion protein, and pacteclizumab, an anti-LTalpha antibody, have been investigated as treatments for rheumatoid arthritis (RA), but they failed in both instances to produce significant clinical efficacy (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115299/)

Mechanisms of Action: FP Inhibitor

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Baminercept

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid|Sjogren's Syndrome|Multiple Sclerosis, Chronic Progressive|Colitis, Ulcerative

Phase 1: Hepatitis C, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ASJ02

P2

Terminated

Sjogren's Syndrome

2015-01-01

2010-019558-42

P2

Completed

Colitis, Ulcerative

2012-10-23

2007-000734-38

P2

Completed

Arthritis, Rheumatoid

2010-02-17

2007-000733-19

P2

Terminated

Arthritis, Rheumatoid

2008-10-09

Recent News Events